Lawson Christine K, Faine Brett A, Rech Megan A, Childs Christopher A, Brown Caitlin S, Slocum Giles W, Acquisto Nicole M, Ray Lance
Department of Pharmacy, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903, USA.
Department of Pharmacy and Department of Emergency Medicine, University of Iowa Hospitals and Clinics, 200 Hawkins Dr., Iowa City, IA 52242, USA.
Am J Emerg Med. 2024 Mar;77:158-163. doi: 10.1016/j.ajem.2023.12.031. Epub 2023 Dec 21.
The preferred vasopressor in post-cardiac arrest shock has not been established with robust clinical outcomes data. Our goal was to perform a systematic review and meta-analysis comparing rates of in-hospital mortality, refractory shock, and hemodynamic parameters in post-cardiac arrest patients who received either norepinephrine or epinephrine as primary vasopressor support.
We conducted a search of PubMed, Cochrane Library, and CINAHL from 2000 to 2022. Included studies were prospective, retrospective, or published abstracts comparing norepinephrine and epinephrine in adults with post-cardiac arrest shock or with cardiogenic shock and extractable post-cardiac arrest data. The primary outcome of interest was in-hospital mortality. Other outcomes included incidence of arrhythmias or refractory shock.
The database search returned 2646 studies. Two studies involving 853 participants were included in the systematic review. The proposed meta-analysis was deferred due to low yield. Crude incidence of in-hospital mortality was numerically higher in the epinephrine group compared with norepinephrine in both studies, but only statistically significant in one. Risk of bias was moderate to severe for in-hospital mortality. Additional outcomes were reported differently between studies, minimizing direct comparison.
The vasopressor with the best mortality and hemodynamic outcomes in post-cardiac arrest shock remains unclear. Randomized studies are crucial to remedy this.
心脏骤停后休克中首选的血管升压药尚未通过有力的临床结局数据得以确立。我们的目标是进行一项系统评价和荟萃分析,比较在接受去甲肾上腺素或肾上腺素作为主要血管升压药支持的心脏骤停后患者中,住院死亡率、难治性休克发生率及血流动力学参数。
我们检索了2000年至2022年期间的PubMed、Cochrane图书馆和CINAHL。纳入的研究为前瞻性、回顾性研究或已发表的摘要,比较去甲肾上腺素和肾上腺素在心脏骤停后休克或心源性休克成人患者中的应用情况以及可提取的心脏骤停后数据。感兴趣的主要结局是住院死亡率。其他结局包括心律失常或难治性休克的发生率。
数据库检索返回2646项研究。两项涉及853名参与者的研究被纳入系统评价。由于纳入研究数量少,未能进行预定的荟萃分析。在两项研究中,肾上腺素组的住院死亡率粗发生率在数值上均高于去甲肾上腺素组,但仅在一项研究中具有统计学意义。住院死亡率的偏倚风险为中度至重度。不同研究报告的其他结局存在差异,难以进行直接比较。
心脏骤停后休克中死亡率和血流动力学结局最佳的血管升压药仍不明确。随机对照研究对于解决这一问题至关重要。